NCT00080808View on ClinicalTrials.gov

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

Alprostadil (E1)

Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly

DRUG

Papaverine

Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly

DRUG

Phentolamine mesylate

Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly

DRUG

Sildenafil citrate

Oral sildenafil as needed

PROCEDURE

conventional surgery

Unilateral cavernous nerve sparing radical retropubic prostatectomy

Trial Locations (1)

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00080808 - Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer | Biotech Hunter | Biotech Hunter